TT16 / Tessa Therap - LARVOL DELTA

VISTA: Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Baylor College of Medicine | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial primary completion date • Bladder Cancer • Breast Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • HER-2

Singapore’s Top-funded Biotech Start-up Announces Liquidation Following Failure of Fundraising (GeneOnline) - "Despite being backed by Singapore’s top investors including Temasek Holdings and the government-linked EDBI, Tessa Therapeutics Ltd. still failed to raise more capital to sustain operations and develop its cell therapies for cancers. As a result, this Singapore-based biotech start-up has announced to its shareholders the intent of initiating liquidation procedures in the near future...Last September, TT11X even won recognition in the 'Most Promising Off-the-Shelf Therapies' category at the Asia-Pacific Cell & Gene Therapy Excellence Awards 2022....Tessa’s other leading pipelines include TT11, an autologous CD30 CAR T-cell therapy for R/R Classical Hodgkin lymphoma, as well as TT16, a combination therapy utilizing HER2-specific autologous CAR VST and an oncolytic virus."

Financing • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Solid Tumor